A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

NCT ID: NCT05874622

Last Updated: 2023-11-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-12
• Study Completion Date: 2023-10-25

Brief Summary

This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

VC005 Tablets Low Dose groups

Group Type: EXPERIMENTAL

VC005 tablets

Intervention Type: DRUG

VC005 groups repeat administration for 4 weeks

VC005 Tablets Medium Dose groups

Group Type: EXPERIMENTAL

VC005 tablets

Intervention Type: DRUG

VC005 groups repeat administration for 4 weeks

VC005 Tablets High Dose groups

Group Type: EXPERIMENTAL

VC005 tablets

Intervention Type: DRUG

VC005 groups repeat administration for 4 weeks

VC005 Tablets Placebo Low Dose groups

Group Type: EXPERIMENTAL

VC005 Tablets Placebo

Intervention Type: DRUG

VC005 placebo groups repeat administration for 4 weeks

VC005 Tablets Placebo Medium Dose groups

Group Type: EXPERIMENTAL

VC005 Tablets Placebo

Intervention Type: DRUG

VC005 placebo groups repeat administration for 4 weeks

VC005 Tablets Placebo High Dose groups

Group Type: EXPERIMENTAL

VC005 Tablets Placebo

Intervention Type: DRUG

VC005 placebo groups repeat administration for 4 weeks

Interventions

VC005 tablets

VC005 groups repeat administration for 4 weeks

Intervention Type: DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The subject or his/her guardian understands and voluntarily signs the informed consent form (ICF);

2. The age at the time of signing the ICF is between 18 and 70 years (including borderline values), regardless of gender;

3. A body mass index [BMI = weight (kg)/height 2 (m2)] of 18 ~30 kg/m2 at the time of screening;

4. Rheumatoid arthritis diagnosed according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 rheumatoid arthritis (RA) classification criteria and at least 3 months of disease duration at the time of the screening visit;

5. A diagnosis of moderately or severely active RA;

6. Have not used any disease-modifying antirheumatic drugs (DMARDs) prior to the first dose of the trial, or have been on a stable dose of methotrexate (MTX) for ≥4 weeks prior to the first dose, or have used methotrexate, salbutamol, or a dose of a drug such as methotrexate. (SASP), chloroquine/hydroxychloroquine, gold, penicillamine, etc., but had stopped using them for ≥3 weeks before the first dose. have stopped using the drug for ≥ 3 months;

7. Subjects who have been stable on NSAIDs prior to the first dose must have had a fixed drug class and a stable dose for ≥4 weeks and continue at a stable dose for the duration of the clinical trial;

8. Subjects who have been stable on oral glucocorticoids prior to the first dose must have been stable for ≥4 weeks at a dose of ≤10 mg/day (prednisone or equivalent dose of other glucocorticoids) and continue at a stable dose for the duration of the clinical trial;

9. The subject is able to communicate well with the investigator and is willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria

1. The subjects who are allergic to the study drug or any of the components of the study drug, or are allergic (multiple drug and food allergies);

2. The subjects have used any of the following medications or treatments:

Tyrosine kinase (JAK) inhibitor class drugs, within 1 month prior to randomization/biologic disease-modifying antirheumatic drugs (bDMARDs) within 5 half-lives prior to randomization or within 3 months,etc；

3. The subjects have a history or evidence of any of the following diseases:

Presence of any systemic inflammatory disease other than RA (except secondary dry syndrome)/lymphoproliferative disease, etc;

4. The presence of any abnormal laboratory test at screening that meets the following criteria (not allowed to receive within 2 weeks prior to screening) Any medical support therapy such as leukocyte boosting, anemia improvement, liver protection and enzyme reduction, blood transfusion, etc;

5. Positive hepatitis B surface antigen (HBsAg) or negative hepatitis B surface antigen, negative hepatitis B surface antibody, positive hepatitis B core antibody (HBcAb) with hepatitis B virus honeybee venom(HBV)-DNA test results above the lower limit of detection; positive hepatitis C antibody (HCVAb) with hepatitis C virus ribonucleic acid (HCV-RNA) test results above the lower limit of detection; positive syphilis spirochete antibody (TPAb) ，etc;

6. Screening period ECG corrected QT interval(QTC): > 470 ms for men and > 480 ms for women, or abnormalities of clinical significance that, in the judgment of the investigator, preclude enrollment;

7. Those with a history of substance abuse or drug use within the past five years;

8. Those who have a positive urine drug screen or alcohol screen;

9. Female patients who are planning to become pregnant or who are pregnant or breastfeeding, or who are unable to use effective contraception throughout the trial and for 6 months after the trial ends;

10. Who, for any reason, are deemed by the investigator to be unsuitable for participation in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yanhua Ding

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Nanya Wang

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Locations

The First Bethune Hospital of Jilin University

Changchun, Jilin, China

Countries

China

Other Identifiers

VC005-103

Identifier Type: -

Identifier Source: org_study_id